High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020–April 2021), Democratic Republic of the Congo

Munyeku-Bazitama, Yannick; Folefack, Gervais T.; Yambayamba, Marc K.; Tshiminyi, Paul M.; Kazenza, Benito M.; Otshudiema, John O.; Guinko, Noe Tondri; Umba, Moreau D.; Mulumba, Anastasie; Baketana, Lionel K.; Mukadi, Patrick K.; Smith, Chris; Muyembe-Tamfum, Jean-Jacques; Ahuka-Mundeke, Steve; Makiala-Mandanda, Sheila

doi:10.3201/eid2901.221009

i

High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020–April 2021), Democratic Republic of the Congo

Supporting Files Public Domain

1 2023
By Munyeku-Bazitama, Yannick ; Folefack, Gervais T. ; Yambayamba, Marc K. ; ...

File Language:

English

Details

Alternative Title:

Emerg Infect Dis
Personal Author:

Munyeku-Bazitama, Yannick ; Folefack, Gervais T. ; Yambayamba, Marc K. ; Tshiminyi, Paul M. ; Kazenza, Benito M. ; Otshudiema, John O. ; Guinko, Noe Tondri ; Umba, Moreau D. ; Mulumba, Anastasie ; Baketana, Lionel K. ; Mukadi, Patrick K. ; Smith, Chris ; Muyembe-Tamfum, Jean-Jacques ; Ahuka-Mundeke, Steve ; Makiala-Mandanda, Sheila
Description:

Serologic surveys are important tools for estimating the true burden of COVID-19 in a given population. After the first wave of SARS-CoV-2 infections, a household-based survey conducted in Kinshasa, Democratic Republic of the Congo, estimated >292 infections going undiagnosed for every laboratory-confirmed case. To ascertain the cumulative population exposure in Kinshasa after the second wave of COVID-19, we conducted a prospective population-based cross-sectional study using a highly sensitive and specific ELISA kit. The survey included 2,560 consenting persons from 585 households; 55% were female and 45% male. The overall population-weighted, test kit-adjusted SARS-CoV-2 seroprevalence was 76.5% (95% CI 74.5%-78.5%). The seroprevalence was 4-fold higher than during the first wave, and positivity was associated with age, household average monthly income, and level of education. Evidence generated from this population-based survey can inform COVID-19 response, especially vaccination campaign strategies in the context of vaccine shortages and hesitancy.
Subjects:

Antibodies, Viral COVID-19 Cross-Sectional Studies Female Humans Male Prospective Studies SARS-CoV-2 Seroepidemiologic Studies
Source:

Emerg Infect Dis. 2023; 29(1):89-97
Pubmed ID:

36573545
Pubmed Central ID:

PMC9796206
Document Type:

Journal Article
Place as Subject:

Democratic Republic of the Congo
Volume:

29
Issue:

1
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

urn:sha256:71d602b920efeaf01a5f051c86ed6e07eb46f6d1eebf8eb9db5cd2bcd26c1359
Download URL:

https://stacks.cdc.gov/view/cdc/127639/cdc_127639_DS1.pdf
File Type:

[PDF - 1.21 MB ]

File Language:

English

ON THIS PAGE

Details Supporting Files

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.